Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Messina, Italy.
Nuclear Medicine Unit, A.R.N.A.S. Ospedali Civico, Di Cristina e Benfratelli, Palermo, Italy.
Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):3925-3939. doi: 10.1007/s00259-021-05352-w. Epub 2021 Apr 13.
The objective of this review was to explore the potential clinical application of unconventional non-amino acid PET radiopharmaceuticals in patients with gliomas.
A comprehensive search strategy was used based on SCOPUS and PubMed databases using the following string: ("perfusion" OR "angiogenesis" OR "hypoxia" OR "neuroinflammation" OR proliferation OR invasiveness) AND ("brain tumor" OR "glioma") AND ("Positron Emission Tomography" OR PET). From all studies published in English, the most relevant articles were selected for this review, evaluating the mostly used PET radiopharmaceuticals in research centers, beyond amino acid radiotracers and 2-[F]fluoro-2-deoxy-D-glucose ([F]FDG), for the assessment of different biological features, such as perfusion, angiogenesis, hypoxia, neuroinflammation, cell proliferation, tumor invasiveness, and other biological characteristics in patients with glioma.
At present, the use of non-amino acid PET radiopharmaceuticals specifically designed to assess perfusion, angiogenesis, hypoxia, neuroinflammation, cell proliferation, tumor invasiveness, and other biological features in glioma is still limited.
The use of investigational PET radiopharmaceuticals should be further explored considering their promising potential and studies specifically designed to validate these preliminary findings are needed. In the clinical scenario, advancements in the development of new PET radiopharmaceuticals and new imaging technologies (e.g., PET/MR and the application of the artificial intelligence to medical images) might contribute to improve the clinical translation of these novel radiotracers in the assessment of gliomas.
本综述旨在探讨非常规非氨基酸正电子发射断层扫描（PET）放射性药物在脑胶质瘤患者中的潜在临床应用。
基于 SCOPUS 和 PubMed 数据库，采用以下字符串进行全面检索策略：（“灌注”或“血管生成”或“缺氧”或“神经炎症”或“增殖”或“侵袭性”）和（“脑肿瘤”或“脑胶质瘤”）和（“正电子发射断层扫描”或“PET”）。从所有以英文发表的研究中，选择最相关的文章进行综述，评估研究中心最常用的 PET 放射性药物，除了氨基酸放射性示踪剂和 2-[F]氟-2-脱氧-D-葡萄糖（[F]FDG），用于评估不同的生物学特征，如灌注、血管生成、缺氧、神经炎症、细胞增殖、肿瘤侵袭性和其他生物学特征在脑胶质瘤患者中。
目前，专门用于评估脑胶质瘤灌注、血管生成、缺氧、神经炎症、细胞增殖、肿瘤侵袭性和其他生物学特征的非氨基酸 PET 放射性药物的应用仍然有限。
考虑到这些放射性药物具有很大的应用潜力，应进一步探索使用研究性 PET 放射性药物，需要专门设计研究来验证这些初步发现。在临床情况下，新的 PET 放射性药物和新的成像技术（如 PET/MR 和人工智能在医学图像中的应用）的发展可能有助于改善这些新型放射性药物在评估脑胶质瘤中的临床转化。
